IP Library Granted Patent US 11,229,631
Granted Patent B2
US 11,229,631 · App. 17/022,803 · Granted Jan 25, 2022

Thiazolecarboxamides and pyridinecarboxamide compounds useful as Pim kinase inhibitors

Inventors: Chu-Biao Xue (Hockessin, DE); Yun-Long Li (Chadds Ford, PA); Hao Feng (Glen Mills, PA); Jun Pan (Media, PA); Anlai Wang (Wilmington, DE); Ke Zhang (Wilmington, DE); Wenqing Yao (Chadds Ford, PA); Fenglei Zhang (Berwyn, PA); Jincong Zhuo (Garnet Valley, PA)
Assignees: Incyte Corporation; Incyte Holdings Corporation
A61K31/444C07D401/14C07D405/14C07D417/14C07D471/04C07D491/048C07D495/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,229,631
App. No.
17/022,803
Granted
Jan 25, 2022
Kind
B2
Abstract

The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.

Claims (4)

1. A compound, which is N-{4-[3-amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein one or more hydrogen atoms are replaced by deuterium, or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. A compound, which is N-{4-[(3R,4R,5S)-3-Amino-4-hydroxy-5-methylpiperidin-1-yl]-7-hydroxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-6-(2,6-difluorophenyl)-5-fluoropyridine-2-carboxamide, wherein one or more hydrogen atoms are replaced by deuterium, or a pharmaceutically acceptable salt thereof.

4. A pharmaceutical composition comprising a compound of claim 3 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2021
From: XUE, CHU-BIAO; LI, YUN-LONG; FENG, HAO; PAN, JUN; WANG, ANLAI; ZHANG, KE; YAO, WENQING; ZHANG, FENGLEI; ZHUO, JINCONG
To: INCYTE CORPORATION
Reel/Frame 055244/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2021
From: INCYTE CORPORATION
To: INCYTE HOLDINGS CORPORATION; INCYTE CORPORATION
Reel/Frame 055244/0055 →
Continuity (10)
Continuation 16685183 · Nov 15, 2019
Continuation 16298601 · Mar 11, 2019
Continuation 15815255 · Nov 16, 2017
Continuation 15373923 · Dec 9, 2016
Continuation 14811038 · Jul 28, 2015
Continuation 14155212 · Jan 14, 2014
Provisional Application 61859118 · Jul 26, 2013
Provisional Application 61790952 · Mar 15, 2013
Provisional Application 61752897 · Jan 15, 2013
Related Publication 20200405702A1 · Dec 31, 2020